Cardiac Autonomic Neuropathy in Type 1 and Type 2 Diabetes Patients

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2018 Aug 29

PMID 30149797

Citations 15

Authors

Anca Motataianu

Smaranda Maier

Zoltan Bajko

Septimiu Voidazan

Rodica Balasa

Adina Stoian

Affiliations

Soon will be listed here.

Abstract

Background: Cardiac autonomic neuropathy (CAN) in diabetes is among the strongest risk markers for future global and cardiovascular mortality. The aim of this study was to analyse CAN prevalence and to compare the associations between CAN, the glycaemic control, cardiovascular risk factors, peripheral neuropathy, retinopathy and macroangiopathy in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM).

Methods: One hundred ninety-five diabetic patients were included in this study. All patients were evaluated for detection of CAN (with standardised cardiovascular reflex tests), diabetes-related microvascular complications (polyneuropathy, retinopathy), common carotid artery intima-media thickness (IMT) and ankle-brachial index (ABI).

Results: The prevalence of CAN was 39.1% in T2DM and 61.8% in T1DM patients. Multivariate logistic regression analysis demonstrated that in T2DM, the odds [OR (95% confidence intervals)] of CAN increased with diabetes duration [1.67(1.42-1.92)], HbA1c [1.74(1.34-2.27)], cholesterol [1.01(1.00-1.01)], triglycerides [1.01(0.99-1.00)], smoking [2.35(1.23-4.49)], systolic blood pressure [1.01(1.00-1.03)], BMI [1.16(1.08-1.24)], glomerular filtration rate [0.91(0.88-0.93)], peripheral neuropathy [25.94(11.04-44.25)], retinopathy [13.13(3.03-84.73)] and IMT [10.12 (7.21-15.32)]. In T1DM, the odds of CAN increased with diabetes duration [1.62(1.13-2.31)], HbA1c [4.49(1.27-15.9)], age of patients [1.14(1.03-1.27)], glomerular filtration rate [0.94(0.89-0.99)], peripheral neuropathy [31.6(4.5-45.8)] and IMT [5.5(2.3-8.3)].

Conclusion: This study indicated that CAN is a more frequent complication in T1DM. Apart from glycaemic control, the existence of CAN is associated with potentially modifiable cardiovascular risk only in T2DM patients. The presence of other micro- and macrovascular complications increases the probability of having CAN in both types of DM (but more pronounced in T2DM).

Citing Articles

Brain-derived neurotrophic factor (BDNF) and other neurotrophic factors in type 2 diabetes mellitus and their association with neuropathy.

Gaur A, Varatharajan S, Balan Y, Taranikanti M, John N, Umesh M Ir J Med Sci. 2024; 193(5):2287-2292.

PMID: 38806878 DOI: 10.1007/s11845-024-03716-3.

Does the Relationship of the Autonomic Symptoms Questionnaire COMPASS 31 with Cardiovascular Autonomic Tests Differ between Type 1 and Type 2 Diabetes Mellitus?.

DIppolito I, Menduni M, DAmato C, Andreadi A, Lauro D, Spallone V Diabetes Metab J. 2024; 48(6):1114-1125.

PMID: 38408489 PMC: 11621654. DOI: 10.4093/dmj.2023.0301.

Effect and Safety of Herbal Medicine Foot Baths in Patients with Diabetic Peripheral Neuropathy: A Multicenter Double-Blind Randomized Controlled Trial.

Huang H, Lin Y, Wei H, Fu Y, Zhou Y, Fang Z Chin J Integr Med. 2024; 30(3):195-202.

PMID: 38374490 DOI: 10.1007/s11655-024-3900-8.

Associations of polyneuropathy with risk of all-cause and cardiovascular mortality, cardiovascular disease events stratified by diabetes status.

Kim K, Lee S, Ahn Y, Ko S, Yun J J Diabetes Investig. 2023; 14(11):1279-1288.

PMID: 37517075 PMC: 10583645. DOI: 10.1111/jdi.14063.

A Review on Autonomic Functional Assessment in Diabetic Patients.

Rukadikar C, Rukadikar A, Kishore S Cureus. 2023; 15(2):e34598.

PMID: 36883072 PMC: 9985918. DOI: 10.7759/cureus.34598.

References

Callaghan B, Hur J, Feldman E . Diabetic neuropathy: one disease or two?. Curr Opin Neurol. 2012; 25(5):536-41. PMC: 4239661. DOI: 10.1097/WCO.0b013e328357a797. View

Calles-Escandon J, Lovato L, Simons-Morton D, Kendall D, Pop-Busui R, Cohen R . Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010; 33(4):721-7. PMC: 2845012. DOI: 10.2337/dc09-1471. View

Granberg V, Ejskjaer N, Peakman M, Sundkvist G . Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathy. Diabetes Care. 2005; 28(8):1959-64. DOI: 10.2337/diacare.28.8.1959. View

Shinozaki N, Yuasa T, Takata S . Cigarette smoking augments sympathetic nerve activity in patients with coronary heart disease. Int Heart J. 2008; 49(3):261-72. DOI: 10.1536/ihj.49.261. View

. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995; 75(14):894-903. DOI: 10.1016/s0002-9149(99)80683-3. View

Constantino M, Molyneaux L, Limacher-Gisler F, Al-Saeed A, Luo C, Wu T . Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 2013; 36(12):3863-9. PMC: 3836093. DOI: 10.2337/dc12-2455. View

Yokoyama H, Yokota Y, Tada J, Kanno S . Diabetic neuropathy is closely associated with arterial stiffening and thickness in Type 2 diabetes. Diabet Med. 2007; 24(12):1329-35. DOI: 10.1111/j.1464-5491.2007.02278.x. View

Gaede P, Vedel P, Larsen N, Jensen G, Parving H, Pedersen O . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348(5):383-93. DOI: 10.1056/NEJMoa021778. View

Ogurtsova K, da Rocha Fernandes J, Huang Y, Linnenkamp U, Guariguata L, Cho N . IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017; 128:40-50. DOI: 10.1016/j.diabres.2017.03.024. View

10.

Ziegler D, Laux G, Dannehl K, Spuler M, Muhlen H, Mayer P . Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med. 1992; 9(2):166-75. DOI: 10.1111/j.1464-5491.1992.tb01754.x. View

11.

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

12.

Vinik A, Maser R, Mitchell B, Freeman R . Diabetic autonomic neuropathy. Diabetes Care. 2003; 26(5):1553-79. DOI: 10.2337/diacare.26.5.1553. View

13.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven P . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2008; 360(2):129-39. DOI: 10.1056/NEJMoa0808431. View

14.

Tesfaye S, Chaturvedi N, Eaton S, Ward J, Manes C, Ionescu-Tirgoviste C . Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005; 352(4):341-50. DOI: 10.1056/NEJMoa032782. View

15.

Meijer J, Smit A, Sonderen E, Groothoff J, Eisma W, Links T . Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. Diabet Med. 2002; 19(11):962-5. DOI: 10.1046/j.1464-5491.2002.00819.x. View

16.

Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R . Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011; 27(7):639-53. DOI: 10.1002/dmrr.1239. View

17.

Ewing D, Martyn C, Young R, CLARKE B . The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985; 8(5):491-8. DOI: 10.2337/diacare.8.5.491. View

18.

Vinik A, Erbas T, Casellini C . Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013; 4(1):4-18. PMC: 3580884. DOI: 10.1111/jdi.12042. View

19.

Dyck P . Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve. 1988; 11(1):21-32. DOI: 10.1002/mus.880110106. View

20.

Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N . The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J Diabetes Complications. 2010; 25(3):159-67. DOI: 10.1016/j.jdiacomp.2010.06.001. View